1. Generics Bulletin
  2. >>Policy & Regulation

European Commission Steps Further Towards ‘Ambitious’ Pharma Legislation Reform

Considering Proposals To Allow Earlier Market Entry For Generics And Biosimilars

 
• By Francesca Bruce

The incentives system, access to medicines, future proofing for novel products and antimicrobial resistance are just some of the topics included in a new consultation.

Touch the future,Interface technology, the future of user experience.
The European Commission Is Consulting On Ambitious Reform

In another step towards what looks set to be a major revision of the EU’s pharmaceutical legislation, the European Commission has published a consultation touching on a wide range of areas that are potentially ripe for reform. It is seeking opinions on measures to improve the incentives system, such as linking incentives to how well a company reports R&D costs, and to drive access to medicines by obliging companies to launch their products in most EU markets.

The commission says that the consultation is “the latest step towards an ambitious reform” and is part of its wider...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Policy & Regulation

Regulatory Recap: EU Pharma Package Progresses Forward With Extended Data Protection

 
• By Urtė Fultinavičiūtė

Generics Bulletin reviews global regulatory developments across the world.

Generic Drug Office’s Policy Staff Returning To US FDA

 
• By Derrick Gingery

The group had been laid off as part of the 1 April reduction-in-force, which lead to missed guidance publication deadlines.

US ‘Red Tape’ Bill Again Targets Biosimilar Interchangeability – Will It Succeed This Time?

 
• By Dave Wallace

After multiple past attempts, US legislators have once again proposed a bill that would make all biosimilars immediately interchangeable upon approval. Could a fresh political context help it to succeed this time?

Sandoz Scores Regional First With EU Launch Of Autoinjectable Stelara Rival

 
• By Adam Zamecnik

Doubling down on the launch of its Stelara biosimilar Pyzchiva in Europe last year, Sandoz has just released an autoinjectable version of the drug, with the aim to offer a more convenient option for ustekinumab patients.

More from Generics Bulletin